Skip to main content
SpringerLink
Log in

Hepatic resection combined with radiofrequency ablation for initially unresectable colorectal liver metastases after effective chemotherapy is a safe procedure with a low incidence of local recurrence

  • Original Article
  • Published:
International Journal of Clinical Oncology Aims and scope Submit manuscript

Abstract

Background

Chemotherapy can lead to tumor down-staging in patients with initially unresectable colorectal liver metastases (CRLM); however, more than half of such cases are still considered to be unresectable because of disease progression, including multiple or bilobar CRLM, and an insufficient predicted remnant liver volume. In addition, there is little evidence supporting the use of radiofrequency ablation (RFA) for patients with CRLM. This study compared the safety and efficacy of hepatic resection (HR) combined with RFA versus HR alone after effective chemotherapy in patients with initially unresectable CRLM.

Methods

Data were prospectively collected on 118 consecutive patients with initially unresectable CRLM who received FOLFOX ± bevacizumab as the first-line chemotherapy. 48 of these patients (41 %) underwent HR or HR + RFA after the chemotherapy. HR was performed in 35 patients (HR group), and HR + RFA in 13 (HR + RFA group).

Results

There was no mortality in either group. Postoperative morbidity rates in the HR group and the HR + RFA group were 17 and 23 %, respectively (P = 0.640). Local recurrence at the RFA site occurred in only one tumor (1.6 % per lesion, 7.7 % per patients). The 3-year progression-free survival was 45.3 % in the HR group and 12.8 % in the HR + RFA group (P = 0.472). The 3-year overall survival rate was 70.4 % in the HR group and 77.1 % in the HR + RFA group (P = 0.627).

Conclusions

These results suggest that HR + RFA after effective chemotherapy is a safe procedure with low local recurrence at the RFA site and is a potentially effective treatment option for patients with initially unresectable CRLM.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3

Similar content being viewed by others

References

  1. Siegel R, Naishadham D, Jemal A (2012) Cancer statistics, 2012. CA Cancer J Clin 62:10–29

    Article  PubMed  Google Scholar 

  2. Kobayashi H, Mochizuki H, Sugihara K et al (2007) Characteristics of recurrence and surveillance tools after curative resection for colorectal cancer: a multicenter study. Surgery 141:67–75

    Article  PubMed  Google Scholar 

  3. McArdle CS, Hole DJ (2002) Outcome following surgery for colorectal cancer. Br Med Bull 64:119–125

    Article  PubMed  Google Scholar 

  4. Stangl R, Altendorf-Hofmann A, Charnley RM et al (1994) Factors influencing the natural history of colorectal liver metastases. Lancet 343:1405–1410

    Article  PubMed  CAS  Google Scholar 

  5. Simmonds PC, Primrose JN, Colquitt JL et al (2006) Surgical resection of hepatic metastases from colorectal cancer: a systematic review of published studies. Br J Cancer 94:982–999

    Article  PubMed  CAS  Google Scholar 

  6. Minagawa M, Makuuchi M, Torzilli G et al (2000) Extension of the frontiers of surgical indications in the treatment of liver metastases from colorectal cancer: long-term results. Ann Surg 231:487–499

    Article  PubMed  CAS  Google Scholar 

  7. Kokudo N, Miki Y, Sugai S et al (2002) Genetic and histological assessment of surgical margins in resected liver metastases from colorectal carcinoma: minimum surgical margins for successful resection. Arch Surg 137:833–840

    Article  PubMed  Google Scholar 

  8. Adam R, Delvart V, Pascal G, et al (2004) Rescue surgery for unresectable colorectal liver metastases downstaged by chemotherapy: a model to predict long-term survival. Ann Surg 240:644–657 (discussion 657–648)

    Google Scholar 

  9. de Gramont A, Figer A, Seymour M et al (2000) Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer. J Clin Oncol 18:2938–2947

    PubMed  Google Scholar 

  10. Giacchetti S, Perpoint B, Zidani R et al (2000) Phase III multicenter randomized trial of oxaliplatin added to chronomodulated fluorouracil–leucovorin as first-line treatment of metastatic colorectal cancer. J Clin Oncol 18:136–147

    PubMed  CAS  Google Scholar 

  11. Goldberg RM, Sargent DJ, Morton RF et al (2004) A randomized controlled trial of fluorouracil plus leucovorin, irinotecan, and oxaliplatin combinations in patients with previously untreated metastatic colorectal cancer. J Clin Oncol 22:23–30

    Article  PubMed  CAS  Google Scholar 

  12. Grothey A, Sargent D, Goldberg RM et al (2004) Survival of patients with advanced colorectal cancer improves with the availability of fluorouracil-leucovorin, irinotecan, and oxaliplatin in the course of treatment. J Clin Oncol 22:1209–1214

    Article  PubMed  CAS  Google Scholar 

  13. Falcone A, Ricci S, Brunetti I et al (2007) Phase III trial of infusional fluorouracil, leucovorin, oxaliplatin, and irinotecan (FOLFOXIRI) compared with infusional fluorouracil, leucovorin, and irinotecan (FOLFIRI) as first-line treatment for metastatic colorectal cancer: the Gruppo Oncologico Nord Ovest. J Clin Oncol 25:1670–1676

    Article  PubMed  CAS  Google Scholar 

  14. Alberts SR, Horvath WL, Sternfeld WC et al (2005) Oxaliplatin, fluorouracil, and leucovorin for patients with unresectable liver-only metastases from colorectal cancer: a North Central Cancer Treatment Group phase II study. J Clin Oncol 23:9243–9249

    Article  PubMed  CAS  Google Scholar 

  15. Skof E, Rebersek M, Hlebanja Z et al (2009) Capecitabine plus Irinotecan (XELIRI regimen) compared to 5-FU/LV plus Irinotecan (FOLFIRI regimen) as neoadjuvant treatment for patients with unresectable liver-only metastases of metastatic colorectal cancer: a randomised prospective phase II trial. BMC Cancer 9:120

    Article  PubMed  Google Scholar 

  16. Van Cutsem E, Rivera F, Berry S et al (2009) Safety and efficacy of first-line bevacizumab with FOLFOX, XELOX, FOLFIRI and fluoropyrimidines in metastatic colorectal cancer: the BEAT study. Ann Oncol 20:1842–1847

    Article  PubMed  Google Scholar 

  17. Folprecht G, Gruenberger T, Bechstein WO et al (2010) Tumour response and secondary resectability of colorectal liver metastases following neoadjuvant chemotherapy with cetuximab: the CELIM randomised phase 2 trial. Lancet Oncol 11:38–47

    Article  PubMed  CAS  Google Scholar 

  18. Beppu T, Hayashi N, Masuda T et al (2010) FOLFOX enables high resectability and excellent prognosis for initially unresectable colorectal liver metastases. Anticancer Res 30:1015–1020

    PubMed  CAS  Google Scholar 

  19. Elias D, De Baere T, Smayra T et al (2002) Percutaneous radiofrequency thermoablation as an alternative to surgery for treatment of liver tumour recurrence after hepatectomy. Br J Surg 89:752–756

    Article  PubMed  CAS  Google Scholar 

  20. Oshowo A, Gillams A, Harrison E et al (2003) Comparison of resection and radiofrequency ablation for treatment of solitary colorectal liver metastases. Br J Surg 90:1240–1243

    Article  PubMed  CAS  Google Scholar 

  21. Tait IS, Yong SM, Cuschieri SA (2002) Laparoscopic in situ ablation of liver cancer with cryotherapy and radiofrequency ablation. Br J Surg 89:1613–1619

    Article  PubMed  CAS  Google Scholar 

  22. Mima K, Beppu T, Masuda T et al (2011) The role of thermal ablation for colorectal liver metastases in the era of effective chemotherapy. Thermal Med 27:1–8

    Article  Google Scholar 

  23. Wicherts DA, de Haas RJ, Adam R (2007) Bringing unresectable liver disease to resection with curative intent. Eur J Surg Oncol 33(Suppl 2):S42–S51

    Article  PubMed  Google Scholar 

  24. Kubota K, Makuuchi M, Kusaka K et al (1997) Measurement of liver volume and hepatic functional reserve as a guide to decision-making in resectional surgery for hepatic tumors. Hepatology 26:1176–1181

    PubMed  CAS  Google Scholar 

  25. Imamura H, Seyama Y, Kokudo N, et al (2003) One thousand fifty-six hepatectomies without mortality in 8 years. Arch Surg 138:1198–1206 (discussion 1206)

    Google Scholar 

  26. Therasse P, Arbuck SG, Eisenhauer EA et al (2000) New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 92:205–216

    Article  PubMed  CAS  Google Scholar 

  27. Japanese Society for Cancer of the Colon and Rectum (2009) Japanese classification of colorectal carcinoma. 2nd English ed. Kanehara Shuppan, Tokyo

  28. Beppu T, Ishiko T, Masuda T et al (2007) Endoscopic Local Ablation Therapy (ELAT) for hepatocellular carcinoma. Thermal Med 23:63–70

    Article  Google Scholar 

  29. Masuda T, Beppu T, Ishiko T, et al (2007) Thermal ablation using Microwave Coagulation Therapy (MCT) and Radiofrequency Ablation (RFA) for hepatocellular carcinoma. Thermal Med 23:123–131

    Google Scholar 

  30. Dodd GD 3rd, Frank MS, Aribandi M et al (2001) Radiofrequency thermal ablation: computer analysis of the size of the thermal injury created by overlapping ablations. Am J Roentgenol 177:777–782

    Article  Google Scholar 

  31. Dindo D, Demartines N, Clavien PA (2004) Classification of surgical complications: a new proposal with evaluation in a cohort of 6336 patients and results of a survey. Ann Surg 240:205–213

    Article  PubMed  Google Scholar 

  32. Clavien PA, Barkun J, de Oliveira ML et al (2009) The Clavien-Dindo classification of surgical complications: five-year experience. Ann Surg 250:187–196

    Article  PubMed  Google Scholar 

  33. Paugam-Burtz C, Janny S, Delefosse D et al (2009) Prospective validation of the “fifty–fifty” criteria as an early and accurate predictor of death after liver resection in intensive care unit patients. Ann Surg 249:124–128

    Article  PubMed  Google Scholar 

  34. Wong SL, Mangu PB, Choti MA et al (2010) American Society of Clinical Oncology 2009 clinical evidence review on radiofrequency ablation of hepatic metastases from colorectal cancer. J Clin Oncol 28:493–508

    Article  PubMed  Google Scholar 

  35. Nicoli N, Casaril A, Abu Hilal M et al (2004) A case of rapid intrahepatic dissemination of hepatocellular carcinoma after radiofrequency thermal ablation. Am J Surg 188:165–167

    Article  PubMed  Google Scholar 

  36. Nikfarjam M, Shereef S, Kimchi ET et al (2009) Survival outcomes of patients with colorectal liver metastases following hepatic resection or ablation in the era of effective chemotherapy. Ann Surg Oncol 16:1860–1867

    Article  PubMed  Google Scholar 

  37. Leung EY, Roxburgh CS, Leen E et al (2010) Combined resection and radiofrequency ablation for bilobar colorectal cancer liver metastases. Hepatogastroenterology 57:41–46

    PubMed  Google Scholar 

Download references

Conflict of interest

All the authors declare no potential conflicts of interest.

Author information

Authors and Affiliations

  1. Department of Gastroenterological Surgery, Graduate School of Medical Sciences, Kumamoto University, 1-1-1 Honjo, Kumamoto, 860-8556, Japan

    Kosuke Mima, Toru Beppu, Akira Chikamoto, Yuji Miyamoto, Shigeki Nakagawa, Hideyuki Kuroki, Hirohisa Okabe, Hiromitsu Hayashi, Yasuo Sakamoto, Masayuki Watanabe & Hideo Baba

  2. Medical Quality Management Center, Graduate School of Social and Cultural Sciences, Kumamoto University, 1-1-1 Honjo, Kumamoto, 860-8556, Japan

    Ken Kikuchi

Authors
  1. Kosuke Mima
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Toru Beppu
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Akira Chikamoto
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Yuji Miyamoto
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Shigeki Nakagawa
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Hideyuki Kuroki
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Hirohisa Okabe
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Hiromitsu Hayashi
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Yasuo Sakamoto
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. Masayuki Watanabe
    View author publications

    You can also search for this author in PubMed Google Scholar

  11. Ken Kikuchi
    View author publications

    You can also search for this author in PubMed Google Scholar

  12. Hideo Baba
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Hideo Baba.

Electronic supplementary material

Below is the link to the electronic supplementary material.

Supplementary material 1 (DOCX 15 kb)

About this article

Cite this article

Mima, K., Beppu, T., Chikamoto, A. et al. Hepatic resection combined with radiofrequency ablation for initially unresectable colorectal liver metastases after effective chemotherapy is a safe procedure with a low incidence of local recurrence. Int J Clin Oncol 18, 847–855 (2013). https://doi.org/10.1007/s10147-012-0471-z

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10147-012-0471-z

Keywords

Search

Navigation